These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
471 related articles for article (PubMed ID: 32511120)
1. Retinal Dystrophies and the Road to Treatment: Clinical Requirements and Considerations. Talib M; Boon CJF Asia Pac J Ophthalmol (Phila); 2020; 9(3):159-179. PubMed ID: 32511120 [TBL] [Abstract][Full Text] [Related]
2. Voretigene Neparvovec: A Review in RPE65 Mutation-Associated Inherited Retinal Dystrophy. Kang C; Scott LJ Mol Diagn Ther; 2020 Aug; 24(4):487-495. PubMed ID: 32535767 [TBL] [Abstract][Full Text] [Related]
7. An Update on Gene Therapy for Inherited Retinal Dystrophy: Experience in Leber Congenital Amaurosis Clinical Trials. Chiu W; Lin TY; Chang YC; Isahwan-Ahmad Mulyadi Lai H; Lin SC; Ma C; Yarmishyn AA; Lin SC; Chang KJ; Chou YB; Hsu CC; Lin TC; Chen SJ; Chien Y; Yang YP; Hwang DK Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33926102 [TBL] [Abstract][Full Text] [Related]
8. Voretigene Neparvovec for the Treatment of RPE65-associated Retinal Dystrophy: Consensus and Recommendations from the Korea RPE65-IRD Consensus Paper Committee. Han J; Joo K; Kim US; Woo SJ; Lee EK; Lee JY; Park TK; Kim SJ; Byeon SH Korean J Ophthalmol; 2023 Apr; 37(2):166-186. PubMed ID: 36950921 [TBL] [Abstract][Full Text] [Related]
10. Frequency of Kahraman NS; Öner A; Özkul Y; Dündar M Turk J Ophthalmol; 2022 Aug; 52(4):270-275. PubMed ID: 36017377 [TBL] [Abstract][Full Text] [Related]
11. Lessons Learned from the Development of the First FDA-Approved Gene Therapy Drug, Voretigene Neparvovec-rzyl. Bennett J; Maguire AM Cold Spring Harb Perspect Med; 2023 May; 13(5):. PubMed ID: 36167727 [TBL] [Abstract][Full Text] [Related]
12. Gene Therapy in Hereditary Retinal Dystrophies: The Usefulness of Diagnostic Tools in Candidate Patient Selections. Malvasi M; Casillo L; Avogaro F; Abbouda A; Vingolo EM Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762059 [TBL] [Abstract][Full Text] [Related]
13. [Gene therapy treatment based on an ophthalmic indication in hereditary retinal dystrophy caused by RPE65 biallelic gene mutation.]. Vizvári E; Smeller L; Jánossy Á; Lőrincz M; Janáky M; Tóth-Molnár E Orv Hetil; 2022 Nov; 163(48):1923-1931. PubMed ID: 36436058 [TBL] [Abstract][Full Text] [Related]
14. RPE65-Associated Retinal Dystrophies: Phenotypes and Treatment Effects with Voretigene Neparvovec. Stingl K; Priglinger C; Herrmann P Klin Monbl Augenheilkd; 2024 Mar; 241(3):259-265. PubMed ID: 38508214 [TBL] [Abstract][Full Text] [Related]
15. [Inherited retinal dystrophy: first results of RPE65 gene replacement therapy in Russia]. Kadyshev VV; Zolnikova IV; Khalanskaya OV; Stepanova AA; Kutsev SI Vestn Oftalmol; 2022; 138(4):48-57. PubMed ID: 36004591 [TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial. Russell S; Bennett J; Wellman JA; Chung DC; Yu ZF; Tillman A; Wittes J; Pappas J; Elci O; McCague S; Cross D; Marshall KA; Walshire J; Kehoe TL; Reichert H; Davis M; Raffini L; George LA; Hudson FP; Dingfield L; Zhu X; Haller JA; Sohn EH; Mahajan VB; Pfeifer W; Weckmann M; Johnson C; Gewaily D; Drack A; Stone E; Wachtel K; Simonelli F; Leroy BP; Wright JF; High KA; Maguire AM Lancet; 2017 Aug; 390(10097):849-860. PubMed ID: 28712537 [TBL] [Abstract][Full Text] [Related]
17. An Economic Evaluation of Voretigene Neparvovec for the Treatment of Biallelic RPE65-Mediated Inherited Retinal Dystrophies in the UK. Viriato D; Bennett N; Sidhu R; Hancock E; Lomax H; Trueman D; MacLaren RE Adv Ther; 2020 Mar; 37(3):1233-1247. PubMed ID: 32034665 [TBL] [Abstract][Full Text] [Related]
18. Voretigene neparvovec-rzyl for treatment of Ciulla TA; Hussain RM; Berrocal AM; Nagiel A Expert Opin Biol Ther; 2020 Jun; 20(6):565-578. PubMed ID: 32149547 [No Abstract] [Full Text] [Related]